{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:17:48Z","timestamp":1793157468691,"version":"4.5.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Antibiotics, steroids, and proton pump inhibitors (PPIs) are suspected to decrease the efficacy of immunotherapy.<\/jats:p><\/jats:sec>Objective<\/jats:title>To explore the association of comedications with overall survival (OS) in patients with advanced non\u2013small-cell lung cancer (NSCLC).<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This nationwide retrospective cohort study used target trial emulations of patients newly diagnosed with NSCLC from January 2015 to December 2022, identified from the French national health care database. Eligible patients were treated with pembrolizumab in a first-line setting and alive 2 months after initiating pembrolizumab. Exclusion criteria included hospitalization for infectious disease, autoimmune disorders, or peptic ulcer disease.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Antibiotic and PPI exposures were defined as at least 2 prescriptions 60 days before to 42 days after pembrolizumab start. Steroid exposure was defined as at least 2 prescriptions 30 days before to 30 days after pembrolizumab start.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was OS. Patients exposed were compared with those without exposure, using inverse probability of treatment weighting (IPTW) to adjust for confounding.<\/jats:p><\/jats:sec>Results<\/jats:title>Between January 2015, and December 2022, 41\u202f529 patients were treated with first line pembrolizumab for advanced disease (27\u202f826 male [67.0%]; median [range] age, 65 [19-97] years; 14\u202f835 [35.7%] treated with pembrolizumab alone; 26\u202f694 [64.3%] treated with pembrolizumab plus chemotherapy). At treatment initiation, 12\u202f898 (41.9%) patients were exposed to antibiotics, 18\u202f210 (59.1%) to steroids, and 16\u202f783 (53.7%) to PPIs. After IPTW, antibiotics (except for macrolide and penicillin) were associated with shorter OS (hazard ratio [HR], 1.08; 95% CI, 1.05-1.12; P<\/jats:italic>\u2009&amp;lt;\u2009.001), but it varied by antibiotic type. Steroids were not associated with OS (HR, 0.98; 95% CI, 0.95-1.02; P<\/jats:italic>\u2009=\u2009.37); however, there was an interaction with pembrolizumab regimen (ie, pembrolizumab alone or with chemotherapy) (P <\/jats:italic>for interaction\u2009&amp;lt;\u2009.001), and there was a dose-dependent association according to daily prednisone-equivalent dose (P<\/jats:italic> for trend\u2009&amp;lt;\u2009.001). Steroids were associated with worse OS when prescribed at doses greater than 20 mg per day for pembrolizumab alone (P <\/jats:italic>for trend\u2009=\u2009.005) and greater than 30 mg per day for pembrolizumab combined with chemotherapy (P<\/jats:italic> for trend\u2009&amp;lt;\u2009.001). PPIs were associated with worse OS (HR, 1.13; 95% CI, 1.10-1.17; P<\/jats:italic>\u2009&amp;lt;\u2009001).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of patients with advanced NSCLC treated with pembrolizumab, exposure to some classes of antibiotics, to steroids (&amp;gt;20 mg per day of prednisone equivalent), and to PPIs was associated with worse OS, indicating that comedications should be monitored carefully in patients with immunotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.29225","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:00:24Z","timestamp":1757516424000},"page":"e2529225","source":"Crossref","is-referenced-by-count":9,"title":["Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non\u2013Small-Cell Lung Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Adrien","family":"Rousseau","sequence":"first","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France"},{"name":"Oncostat U1018, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Simon-Tillaux","sequence":"additional","affiliation":[{"name":"Oncostat U1018, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France"},{"name":"Biostatistics and Epidemiology Office, Gustave Roussy, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Michiels","sequence":"additional","affiliation":[{"name":"Oncostat U1018, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France"},{"name":"Biostatistics and Epidemiology Office, Gustave Roussy, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Derosa","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1015, Equipe Labellis\u00e9e, Ligue Nationale Contre le Cancer, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Laparra","sequence":"additional","affiliation":[{"name":"Department of Drug Development, Gustave Roussy, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernelle","family":"Lavaud","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Frelaut","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Parisi","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Gazzah","sequence":"additional","affiliation":[{"name":"Department of Drug Development, Gustave Roussy, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Foulon","sequence":"additional","affiliation":[{"name":"Oncostat U1018, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France"},{"name":"Biostatistics and Epidemiology Office, Gustave Roussy, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"issue":"19","key":"zoi250824r1","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi250824r2","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi250824r3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jamaoncol.2023.2296","article-title":"Association of corticosteroids with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.","volume":"9","author":"Lefort","year":"2023","journal-title":"JAMA Oncol"},{"issue":"17","key":"zoi250824r4","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1200\/JCO.22.00074","article-title":"Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study.","volume":"41","author":"Eng","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi250824r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.22915","article-title":"Concomitant proton pump inhibitor use with pembrolizumab monotherapy vs immune checkpoint inhibitor plus chemotherapy in patients with non-small cell lung cancer.","volume":"6","author":"Kawachi","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi250824r6","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1158\/2159-8290.CD-21-0236","article-title":"Microbiota-centered interventions: the next breakthrough in immuno-oncology?","volume":"11","author":"Derosa","year":"2021","journal-title":"Cancer Discov"},{"issue":"7","key":"zoi250824r7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jtho.2020.03.002","article-title":"NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis.","volume":"15","author":"Lurienne","year":"2020","journal-title":"J Thorac Oncol"},{"key":"zoi250824r8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1075593","article-title":"A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors.","volume":"13","author":"Crespin","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"zoi250824r9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1929727","article-title":"Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer.","volume":"10","author":"Qin","year":"2021","journal-title":"Oncoimmunology"},{"issue":"7","key":"zoi250824r10","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1111\/bcp.15276","article-title":"The association between proton pump inhibitor use and systemic anti-tumour therapy on survival outcomes in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.","volume":"88","author":"Wei","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"zoi250824r11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.clgc.2022.07.003","article-title":"Efficacy and safety of concomitant proton pump inhibitor and nivolumab in renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study.","volume":"20","author":"Rassy","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"14","key":"zoi250824r12","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-22-3181","article-title":"Corticosteroids and cancer immunotherapy.","volume":"29","author":"Goodman","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"28","key":"zoi250824r13","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"issue":"24","key":"zoi250824r14","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data.","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"zoi250824r15","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology.","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"zoi250824r16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-074626","article-title":"Development of the transparent reporting of observational studies emulating a target trial (TARGET) guideline.","volume":"13","author":"Hansford","year":"2023","journal-title":"BMJ Open"},{"key":"zoi250824r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100970","article-title":"Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study.","volume":"43","author":"Rousseau","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"3","key":"zoi250824r18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/bmjebm-2018-111069","article-title":"Causal inference for clinicians.","volume":"24","author":"Stovitz","year":"2019","journal-title":"BMJ Evid Based Med"},{"issue":"1","key":"zoi250824r19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/EDE.0000000000001808","article-title":"A structural description of biases that generate immortal time.","volume":"36","author":"Hern\u00e1n","year":"2025","journal-title":"Epidemiology"},{"issue":"4","key":"zoi250824r20","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1568812","article-title":"Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors.","volume":"8","author":"Elkrief","year":"2019","journal-title":"Oncoimmunology"},{"issue":"6","key":"zoi250824r21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/aje\/kwac014","article-title":"On variance of the treatment effect in the treated when estimated by inverse probability weighting.","volume":"191","author":"Reifeis","year":"2022","journal-title":"Am J Epidemiol"},{"issue":"2","key":"zoi250824r22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.","volume":"28","author":"Derosa","year":"2022","journal-title":"Nat Med"},{"issue":"6649","key":"zoi250824r23","doi-asserted-by":"publisher","DOI":"10.1126\/science.abo2296","article-title":"A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.","volume":"380","author":"Fidelle","year":"2023","journal-title":"Science"},{"issue":"1","key":"zoi250824r24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003779","article-title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy.","volume":"10","author":"Jing","year":"2022","journal-title":"J Immunother Cancer"},{"key":"zoi250824r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2021.102095","article-title":"The immunomodulatory effects of macrolide antibiotics in respiratory disease.","volume":"71","author":"Pollock","year":"2021","journal-title":"Pulm Pharmacol Ther"},{"issue":"6","key":"zoi250824r26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jinf.2019.10.008","article-title":"The effect of antibiotics on the composition of the intestinal microbiota\u2014a systematic review.","volume":"79","author":"Zimmermann","year":"2019","journal-title":"J Infect"},{"issue":"13","key":"zoi250824r27","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1016\/j.cell.2024.05.029","article-title":"Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome.","volume":"187","author":"Derosa","year":"2024","journal-title":"Cell"},{"issue":"1","key":"zoi250824r28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2081010","article-title":"Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors.","volume":"11","author":"Tomita","year":"2022","journal-title":"Oncoimmunology"},{"issue":"10","key":"zoi250824r29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors.","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"zoi250824r30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy.","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"zoi250824r31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.","volume":"6","author":"Giles","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"6","key":"zoi250824r32","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jtho.2022.02.003","article-title":"Efficacy of atezolizumab in patients with advanced NSCLC receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomized control trials.","volume":"17","author":"Hopkins","year":"2022","journal-title":"J Thorac Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2838685\/rousseau_2025_oi_250824_1756925728.92736.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:00:24Z","timestamp":1757516424000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2838685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.29225","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}